Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03698864 | A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica | PHASE2 | COMPLETED | 12 | — | — | Nov 7, 2018 | Feb 25, 2020 | Oct 3, 2022 | 2 | United States |
Evaluation of Adverse Events/Serious Adverse Events (by type, severity, and relatedness)
| Arm | Type | Description |
|---|---|---|
| PCS499 900mg twice a day | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PCS499 | DRUG | PCS499 900mg twice a day with food |
Inclusion Criteria: 1. Male or female patients age 18 to 80 years of age, inclusive, at Screening. 2. Biopsy-confirmed diagnosis of NL. Biopsies of continually active lesions performed outside of this clinical study will need to be reviewed and the diagnosis confirmed by the study pathologist. For ...